Ireland
--:--IST
Recruiting Not applicable

Hypothermia Versus Normothermia After Extracorporeal Cardiopulmonary Resuscitation for Out-of-hospital Cardiac Arrest

NCT06776549 · tracked via the Priya Life Science Japan tracker
Sponsor
Kagawa University
Phase
Not applicable
Started
2025-01-06
Last updated
2026-08-07

Condition(s) studied

Out-of-hospital Cardiac Arrest (OHCA)ECMO TreatmentTemperaturePost Cardiac Arrest Syndrome

Investigational drug(s) / intervention(s)

Temperature controlTemperature control

Temperature control: Procedure: Temperature control at 33-34 °C In the hypothermia group, patients receiving ECPR will be immediately cooled to 33ºC-34ºC with ECMO using a heat exchanger. After reaching this targeted temperature, the maintenance phase will start, and the target temperature will be kept at 33ºC-34°C. The maintenance phase will end 24 h after reaching this targeted temperature. Subsequently, rewarming to 36ºC-37ºC will be conducted in 24 h. After the rewarming, the temperature will be kept in the range of 36ºC-37.5ºC for 24 h after rewarming or until the end of ECMO, and should not exceed 37.5ºC. Other interventions, such as sedation, administration of neuromuscular blocking agents, antipyretics, and catecholamines, as well as mechanical circulatory support, are optional and performed at the patient's discretion.

Temperature control: Procedure: Temperature control at 36 °C In the normothermia group receiving ECPR, the temperature of 36ºC will be immediately reached with ECMO using a heat exchanger. After reaching this targeted temperature, the maintenance phase will start, and the target temperature will be maintained at 36ºC. The maintenance phase will end 24 h after reaching this targeted temperature. Then, rewarming to 36ºC-37ºC will be conducted in 24 h. After the rewarming, the temperature will be kept in the range of 36ºC-37.5ºC for 24 h after rewarming or until the end of ECMO, and should not exceed 37.5ºC. Other interventions, such as sedation, administration of neuromuscular blocking agents, antipyretics, and catecholamines, as well as mechanical circulatory support, are optional and performed at the patient's discretion.

Study summary

The SAVE-J NEUROTHERM trial is a cluster randomized trial that evaluated and compared the mortality risk, neurological outcomes, and adverse events between patients who underwent hypothermia and those who underwent normothermia after extracorporeal cardiopulmonary resuscitation for out-of-hospital cardiac arrest.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * OHCA * Age of 18-75 years, known or estimated * An initial cardiac arrest rhythm of ventricular fibrillation/pulseless ventricular tachycardia or pulseless electrical activity Exclusion Criteria: * ECMO initiated after sustained return of spontaneous circulation (ROSC) and patients with sustained ROSC before ECMO initiation * OHCA of presumed non-cardiac etiology * Time from emergency call or witnessed arrest to hospital arrival of \>60 min * Time from hospital arrival to ECMO initiation of \>60 min * Pre-hospital ECPR * Unavailability of the ECMO heat exchanger for temperature control * Glasgow Coma Scale score before temperature control of \>8 * Core body temperature upon hospital arrival of ≤32ºC * Surgical intervention before temperature control (e.g., surgical intervention for the primary disease or complications related to resuscitation/ECMO procedures) * Do Not Attempt Resuscitation) order confirmed prior to temperature control * Limitations in intensive care before temperature control * Known cerebral performance category (CPC) of 3-4 before cardiac arrest * Known chronic obstructive pulmonary disease with home oxygen therapy * Known or suspected pregnancy * Concomitant illness, such as malignancy, shortens life expectancy (180-day survival unlikely) * Consent not obtained or withdrawn by the participant or surrogate * Other reasons, physician's decision not to enroll the patient

Primary outcome measure(s)

  • Survival — At discharge (approximately 25 days)

Trial sites (29)

FacilityCityRegionStatus
Kurume University Hospital Kurume Fukuoka Recruiting
Asahikawa Medical University Hospital Asahikawa Hokkaido Not Yet Recruiting
Sapporo Medical University Hospital Sapporo Hokkaido Recruiting
Hokkaido University Hospital Sapporo Hokkaido Recruiting
Hyogo Prefectural Kakogawa Medical Center Kakogawa Hyōgo Recruiting
Hyogo Emergency Medical Center Kobe Hyōgo Recruiting
Toyooka Public Hospital Toyooka Hyōgo Recruiting
Hitachi General Hospital Hitachi-shi Ibaraki Recruiting
Kagawa University Hospital Kita-gun Kagawa-ken Recruiting
Oshima Prefectural Hospital Amami Kagoshima-ken Recruiting
Ebina General Hospital Ebina Kanagawa Recruiting
Saiseikai Yokohamashi Tobu Hospital Yokohama Kanagawa Recruiting
Kyoto Second Red Cross Hospital Kyoto Kyoto Not Yet Recruiting
Tohoku University Hospital Sendai Miyagi Recruiting
Sendai Medical Center Sendai Miyagi Recruiting
Okayama University Hospital Okayama Okayama-ken Recruiting
Tsuyama Chuo Hospital Tsuyama Okayama-ken Recruiting
Okinawa Prefectural Nanbu Medical Center & Children's Medical Center Shimajiri-gun Okinawa Recruiting
Osaka Saiseikai Senri Hospital Suita Osaka Recruiting
Saitama Red Cross Hospital Saitama Saitama Recruiting
Tottori Prefectural Central Hospital Tottori-shi Tottori Recruiting
St. Luke's International Hospital Tokyo Japan Recruiting
Institute of Science Tokyo Hospital Tokyo Japan Recruiting
Nippon Medical School Hospital Tokyo Japan Recruiting
Tokyo Metropolitan Bokutoh Hospital Tokyo Japan Recruiting
Keio University Hospital Tokyo Japan Recruiting
Japanese Red Cross Musashino Hospital Tokyo Japan Recruiting
Tokyo Metropolitan Tama Medical Center Tokyo Japan Recruiting
National Hospital Organization Disaster Medical Center Tokyo Japan Recruiting

More Kagawa University trials in Japan

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06776549 on ClinicalTrials.gov ↗ ← All trials in Japan